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Background: Human urokinase-type plasminogen activator has been implicated
in the regulation and control of basement membrane and interstitial protein
degradation. Because of its role in tissue remodeling, urokinase is a central
player in the disease progression of cancer, making it an attractive target for
design of an anticancer clinical agent. Few urokinase inhibitors have been
described, which suggests that discovery of such a compound is in the early
stages. Towards integrating structural data into this process, a new human
urokinase crystal form amenable to structure-based drug design has been used
to discover potent urokinase inhibitors. 
Results: On the basis of crystallographic data, 2-naphthamidine was chosen as
the lead scaffold for structure-directed optimization. This co-crystal structure
shows the compound binding at the primary specificity pocket of the trypsin-like
protease and at a novel binding subsite that is accessible from the 8-position of
2-napthamidine. This novel subsite was characterized and used to design two
compounds with very different 8-substituents that inhibit urokinase with Ki
values of 30–40 nM.
Conclusions: Utilization of a novel subsite yielded two potent urokinase
inhibitors even though this site has not been widely used in inhibitor
optimization with other trypsin-like proteases, such as those reported for
thrombin or factor Xa. The extensive binding pockets present at the substrate-
binding groove of these other proteins are blocked by unique insertion loops in
urokinase, thus necessitating the utilization of additional binding subsites.
Successful implementation of this strategy and characterization of the novel site
provides a significant step towards the discovery of an anticancer clinical agent.
Introduction
Urokinase, a trypsin-like serine protease, degrades base-
ment membranes and interstitial matrices via a cascade
mechanism involving plasminogen and metalloproteases
[1–3]. This tissue remodeling is part of the disease pro-
gression in cancer, arthritis [4,5], atherosclerosis [6,7],
and post-myocardial infarction heart rupture [8]. Cancer
invasion and metastasis are the primary causes of mortal-
ity and  morbidity of malignancy [9]. In order to take
effect, invasion and metastasis require the degradation of
basement membranes and other extracellular protein
structures. High levels of urokinase activity are associ-
ated with many cancers, and furthermore, increased
urokinase activity is an independent predictor of the dis-
eased state [10]. Tumors invade and metastasize more
slowly in urokinase-knockout mice than they do in
control animals [11]. Inhibitors of urokinase have been
reported to slow tumor metastasis and the growth of the
primary tumor [12–16]. These data suggest that inhibi-
tion of urokinase activity might retard the progression of
cancer in humans.
In addition to urokinase enzymatic activity, other compo-
nents of the urokinase–plasminogen pathway have also
been implicated in the growth and invasion of tumors.
The N-terminal growth-factor-like domain of urokinase
binds to its cellular receptor urokinase-type plasminogen
activator receptor (uPAR). Inhibition of this interaction
has been shown to diminish the growth of tumors in
xenograft models [17,18]. Plasminogen activator inhibitors
1 and 2 (PAI1 and PAI2) have also been implicated in the
progression of tumors. Although high levels of PAI2 have
been associated with better prognosis in humans [19,20],
high concentrations of PAI1 have, paradoxically, been
show to be associated with poor prognosis and lack of
tumor progression [21–25].
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Despite the potential clinical significance of blocking
urokinase activity, few urokinase inhibitors have been
reported. A peptide that selects for urokinase over tissue
plasminogen activator has been identified using phage
display. This peptide was engineered into PAI1 providing a
specific macromolecular serpin inhibitor [26]. Inhibitor
binding in the substrate groove has been visualized in the
reported crystal structure of Glu-Gly-Arg-chloromethylke-
tone–urokinase [27]. In addition to these peptide-derived
inhibitors, small-molecule inhibitors [28–32] have also been
reported. These contain a positively charged group that is
expected to bind in the primary binding pocket of uroki-
nase. Although most compounds are reported to inhibit in
the micromolar range, two amidine-containing series are
submicromolar inhibitors of urokinase. Two compounds
from one series, B428 and B623, inhibit urokinase with an
IC50 of 370 nM and 70 nM, respectively [29,30], whereas in
another series an analog of the thrombin inhibitor N-(4-
toluene-sulphonyl)-DL-p-amidinophenyl-alanyl-piperidine
(TAPAP) inhibits with a Ki of 410 nM [33]. Co-crystal
structures in both series have been completed, B428 in
complex with urokinase [34] and the TAPAP analog in
complex with trypsin [33]. Both compounds bind at the S1
pocket although the binding mode of the TAPAP analog to
trypsin would be sterically blocked in urokinase [33]. This
work provides an important starting point for the design of
more potent urokinase inhibitors.
Although urokinase inhibitors and structural data are avail-
able, there is a lack of reports describing structure-
directed optimization of urokinase inhibitors. This is
despite the large amount of literature available describing
drug-design programs for the structurally similar blood-
clotting enzymes thrombin and factor Xa [35–38]. The
role of urokinase in the mechanism of tumor metastasis
indicates that structural and functional characterization of
the urokinase active site and the discovery of more potent
small-molecule inhibitors should provide a significant step
towards obtaining an anticancer clinical agent. To achieve
this step a new crystal form of human urokinase [34], that
diffracts to high resolution and permits complex formation
by the compound soaking method, has been used to
determine co-crystal structures with a series of small-mol-
ecule noncovalent inhibitors. The process provided char-
acterization of a novel binding subsite adjacent to the
primary binding pocket and yielded two of the most
potent urokinase inhibitors reported to date.
Results and discussion
Identification of binding pockets and subsites for
structure-directed drug design
Examination of the urokinase substrate-binding groove
reveals that, apart from the primary binding S1 pocket, this
site is relatively featureless when compared with other
trypsin-like serine proteases (Figure 1). For this family of
proteins, positively charged small-molecule inhibitors
make a salt bridge with Asp189 in the S1 pocket [39].
Serine proteases such as thrombin, factor Xa, or tissue
plasminogen activator [27,40–42], however, also have
other secondary binding sites at S2 and/or S4 of the sub-
strate-binding groove [33,38]. In urokinase, the size of S2
and S4 is greatly reduced owing to a two-residue insertion
at position 97 (chymotrypsin numbering system), which
effectively blocks both sites (Figure 1). Thus, urokinase
inhibitors require S1 as the anchor site but depend upon
smaller pockets and/or subsites on the surface of the
enzyme for lead optimization. 
A number of amidine-based urokinase inhibitors have
been reported [43] including benzamidine (Ki = 1 mM),
5-amidino-indole (Ki = 131 µM) [28], benzo(b)thiophene-
2-carboxamidine (IC50 = 3.7 µM, starting scaffold for B428)
[29,30], and 2-naphthamidine (Ki = 5.5 µM) [31]. These
inhibitors are expected to bind at S1, as demonstrated by
the co-crystal structure of B428–urokinase [34] and also
because of their net positive charge. Of these scaffolds,
benzo(b)thiophene-2-carboxamidine and 2-naphthamidine
are the most potent and exhibit selectivity against tissue
plasminogen activator and plasmin. This selectivity might
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Figure 1
GRASP [58] surface representation of urokinase. Residues at the
active site are labeled in black and binding residues within pockets in
white. The substrate-binding groove consists of the S1, S2 and S4
pockets; the S1β subsite is directly adjacent to the substrate-binding
groove. The insertion loop that partially obstructs S4 is labeled IL. The
surface is colored according to electrostatic potential: red, negative;
blue, positive.
limit antifibrinolytic side effects in vivo [29–31]. To pick
the best starting scaffold for structure-based drug design,
the co-crystal structure for each scaffold bound to uroki-
nase was examined and compared.
The crystal structure of 4-iodo benzo(b)thiophene-2-car-
boxamidine (B428) at 2.0 Å resolution [34] shows that the
compound binds at S1 (Figure 2a, orange) and that the
inhibitor’s 4-position is directed towards a novel sub-
pocket termed S1β [34]. The S1β site is bounded by
residues Gly218 and Ser146, the Cys191–Cys220 disulfide
bridge, the sidechain of Lys143 and part of Gln192. In
B428, the 4-iodo interacts at the entrance of S1β and
results in an increase in potency from an IC50 of 3.7 µM to
an IC50 of 0.320 µM [29,30], making this an attractive site
for lead optimization. As reported previously [34],
however, the 5- and 6-positions of B428 are less optimally
situated for accessing other subpockets on the molecule
(Figure 2a). More specifically, the substitution vector from
the 5-position is directed towards Gln192 and out into the
bulk solvent, whereas the 6-position is in close contact
with Ser195 Oγ. The co-crystal structure of B428–uro-
kinase reveals direct accessibility to the S1β site but not
towards any other sites.
The co-crystal structure of 2-napthamidine urokinase
(Figure 2b; Table 1) shows the inhibitor bound at the S1
pocket. This is similar to the binding observed for substi-
tuted factor Xa naphthamidine inhibitors BM12.1700,
BX5633 and/or DX-9065a when complexed with factor Xa,
thrombin or trypsin [38,44,45]. In urokinase, the hydrogen
bonding of the amidine nitrogens and the conformation of
Asp189 is the same as observed for the thrombin and
trypsin complex structures, and the naphthalene group is
in van der Waals contact with the interior of the S1 pocket.
When naphthamidine inhibitors bind to factor Xa and
thrombin a conformational shift of residues 191–193 by
1.5–2.0 Å is observed [38,44]; comparisons of naphtami-
dine-bound urokinase with the native protein show no
such shift to occur.
Unlike B428, 2-naphthamidine presents more options for
substitution. The naphthamidine 1-, 3- and 4-positions are
in close contact with the protein and are therefore not open
to further substitution (see ring-numbering system in
Table 2 or Figure 2b). The 5-position points underneath
the sidechain of Ser195 and might accommodate a small
group, whereas the 6-, 7- and 8-positions might accommo-
date much larger substitutions. The 6-position points
above S2 and substitutions here are projected to interact
with subsites above the peptide-binding groove. This is in
contrast to the 6-position of B428 (Figure 2b), which is in
close contact with Ser195 Oγ. The 7-position of 2-naph-
thamidine points towards Gln192 and bulk solvent and
substitutions at this site will have limited interactions with
urokinase. Naphthamidines with 7-substitutions such as
compound 2 (Table 2) are, within error, equipotent to the
parent compound. This is in contrast to the observation
that 7-substituted naphthamidines are potent factor Xa
inhibitors [38,44,45]. The 7-substituted factor Xa inhibitors
use a second binding site at S4 that is blocked and, there-
fore, not accessible in the urokinase structure. The 8-posi-
tion of 2-napthamidine points towards the S1β pocket
(Figure 2), which is an important site for binding in the
benzo(b)thiophene-2-carboxamidine series of inhibitors
[34]. No 8-substituted naphthamidine, however, has been
reported as a trypsin-like protease inhibitor. Examination
of the structural data, therefore, shows that both B428 and
Research Article  Design of potent urokinase inhibitors Nienaber et al. 555
Figure 2
Crystal structures for choosing a starting
scaffold. (a) Overlay of naphthamidine
(purple) and B428 (orange) bound to
urokinase showing a similar binding mode for
the two amidine groups but different vectors
toward the S1β pocket. Even though the
naphthamidine 6-position and B428
5-position overlap, the vectors from these
sites are very different. Partial numbering of
the B428 (orange) and naphthamidine
(purple) rings are also color coded.
(b) Crystal structure of naphthamidine
(purple) bound at the active site S1 pocket of
urokinase. Several residues participate in
hydrogen bonds between the amidine group
and protein (red dashed lines): Asp189 Oδ1
(3.1 Å), Ser190 Oγ (3.0 Å), Asp189 Oδ2
(2.9 Å) and Gly218 O (2.8 Å). Residues
within the S1 pocket that are in van der Waals
contact with the inhibitor include Val213,
Ser190 and Asp194 as well as the rim that
consists of the Cys191–Cys220 disulfide
bridge, and the mainchain atoms of
Ser214–Cys220 and Gln192–Cys191.
Hydrogen bonding between an ordered
solvent molecule bound at S1β and the protein
is also depicted (red dashed lines).
Numbering of the naphthamidine ring system
is shown in purple.
2-naphthamidine might access S1β (Figure 2a). As naph-
thamidine appears more optimally situated to access addi-
tional subpockets near the substrate binding groove in
addition to S1β, 2-napthamidine was chosen as the lead
scaffold over benzo(b)thiophene-2-carboxamidine. 
The 8-position of 2-naphthamidine was chosen as the
initial site for optimization because interactions at the S1β
pocket have been demonstrated to confer an increased
potency in the benzo(b)thiophene-2-carboxamidine series.
Can this boost in potency be obtained in a naphthamidine
inhibitor by a transfer of functionality? An overlay of B428
and 2-napthamidine shows that the substitution vector of
the 8-position of 2-napthamidine is different from that of
the 4-position of benzo(b)thiophene-2-carboxamidine,
thus suggesting that a direct transfer of functionality
might not work (Figure 2a). Given that the iodo-group of
B428 interacts with a bridge between S1 and S1β, it is also
likely that increased potency is dependent on the specific
geometry of the interaction and that this is not available
for the 2-naphthamidine. This was supported by the
observation that 8-iodo-2-napthamidine bound with nearly
the same potency (Ki = 2.7 µM; compound 3 Table 2) as
the parent. Thus, it is unlikely that the B428
structure–activity relationships at the S1β pocket can trans-
late to the 2-naphthamidines.
The S1β pocket is a shallow subsite that has not been
widely used for structure-based drug design of other serine
protease inhibitors. One inhibitor, terphenylbisamidine,
has been shown to access S1β in trypsin and to hydrogen
bond with Asn143 [46]. Because urokinase has a lysine at
position 143, however, this inhibitor’s substituent would
probably interact unfavorably at the S1β site of urokinase.
The S1β subpocket contains a number of polar groups
including Gln192 N Gln192 Nε2(Oε1), Lys143 Nζ, Ser146
Oγ and Ser146 O with Gly216 O, Gly218 N and Gly218 O
at the bridge from S1. Furthermore, an ordered solvent
molecule is found to occupy this site and hydrogen bond
with Gln192 O/N (3.3 Å), Lys143 Nζ (3.3 Å) and possibly
Ser146 O (3.7 Å) (Figure 2b). Consequently, hydrophilic
8-substitutions were synthesized to interact with the S1β
pocket. One group which conferred a tenfold potency
increase was benzylcarbamate (Ki = 0.17 µM; compound 5
Table 2). This substitution contains both hydrophobic and
hydrophilic components, and from molecular modeling the
group is predicted to be too large to be fully accommo-
dated at S1β. To understand the specific interactions of
benzylcarbamate, a crystal structure was determined at
2.0 Å resolution (Table 1).
The crystal structure of 8-benzylcarbamyl 2-aminonaph-
thamidine (compound 5) reveals a number of important
binding interactions and suggests a strategy for the next
round of the design cycle. The electron-density maps
reveal strong density for all atoms of the inhibitor except
for the benzyl phenyl (Figure 3a) and show the 8-carba-
mate bound at S1β (Figure 3b). The ordered solvent found
at S1β is not displaced by the carbamate and is hydrogen
bonded with the carbonyl oxygen (2.7 Å) of the inhibitor.
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Table 1
X-ray data and model statistics.
Data set –H* –NH2* –NHCOObenz* –NHCOOMe* –NHpyr*
Space group P212121 P212121 P212121 P212121 P212121
Cell dimensions (a,b,c) 55.30, 52.78, 79.78 55.28, 52.76, 79.67 54.98, 52.67, 79.68 55.09, 52.59, 79.40 55.62, 52.63, 79.53
Resolution range (Å) 40–2.2 40–2.0 50–2.0 40–1.84 50–1.85
Total reflections 48,181 86,588 130,245 164,339 189,986
Unique reflections 11,611 16,421 15,917 21,751 20,041
Completeness (%)
overall (final shell) 93.2 (96.7) 99.5 (99.1) 99.0 (100.0) 97.9 (99.0) 96.5 (94.4)
Rmerge† (final shell) 6.2 (27.4) 12.9 (37.1) 5.2 (18.1) 13.8 (48.1) 5.0 (19.4)
R factor‡ (Rfree§) 20.6 (29.9) 22.2 (28.3) 21.2 (27.9) 20.5 (24.4) 22.2 (28.4)
Rms deviations from ideality#
bonds (Å) 0.025 0.021 0.028 0.028 0.023
angles (°) 2.83 3.07 2.13 2.92 2.71
Average B factors¶ (Å2)
protein 12.02 9.75 13.93 12.23 13.46
solvent 13.69 16.52 19.72 21.13 17.20
sulfate 25.91 26.66 30.72 29.95 29.78
inhibitor 5.43 9.73 9.304 10.05 7.39
*The substituent R is given at the top of the table. †Rsym = Σ ((I – <I>) ** 2) / Σ (I ** 2). ‡Rfactor = Σ |Fo–Fc|/Σ |Fo|. §Value of the
R factor where 10% of the data were randomly removed from the refinement. #Values were calculated using the parhcskx.pro
parameters [56] in X-PLOR. ¶Average B factor is for atoms visible in the electron-density maps.
R NH
NH2
The carbamyl nitrogen donates a hydrogen bond to
Gly216 O (3.4 Å). In addition to these hydrophilic interac-
tions, the carbamyl group is also in van der Waals contact
with Gly218, the Cys191–Cys220 disulfide, Gln192 and
Ser146, with a close packing interaction between the car-
bamyl ester oxygen and Gly218 Cα (3.0 Å; Figure 3b).
The hydrophobic and hydrophilic interactions between
the carbamyl and S1β are probably responsible for the
binding potency conferred by the benzylcarbamyl group.
Conversely, the phenyl group points into the bulk solvent
and is disordered in the electron-density map. This disor-
dered group is unlikely, therefore, to contribute to the
binding of the 8-benzylcarbamyl compound and in fact,
might cost binding energy due to the placing of a
hydrophobic group into the bulk solvent.
Because the phenyl group in compound 5 is disordered
in the electron density it was removed resulting in the
production of 8-methylcarbamyl-2-naphthamidine (com-
pound 6 Table 2). Compound 6 showed a significant
increase in inhibitory potency (Ki = 0.04 µM), thus pro-
viding one of the most potent nonpeptidic urokinase
inhibitor reported to date. The crystal structure of the
8-methylcarbamyl compound (Figure 3c) depicts a
hydrogen-bonding geometry for the carbamyl group
similar to that of benzyl carbamate in addition to
increased hydrophobic packing interactions. Further-
more, removal of the phenyl group of the benzyl sub-
stituent allows a rotation about the N–C bond so that the
remaining methyl group is closely packed within a
hydrophobic dimple. This dimple is composed of Cα and
Cβ of Ser146 and Cys220 (Figure 3c). The phenyl group
of the benzyl substituent prevents this close interaction
and its removal results in more optimal binding at S1β. 
Comparison of the inhibitory potency of 2-napthamidine
and 8-methylcarbamyl 2-naphthamidine suggests that
hydrophobic and hydrophilic interactions from the
methylcarbamyl contribute about 100-fold to the Ki or
approximately 3 kcal of binding energy relative to the
naphthamidine parent. The ability to accurately predict
binding energies computationally has been a difficult task
given the contributions of numerous variables such as des-
olvation, inhibitor structure re-organization and the series
of ligand–protein interactions [47]. To estimate the ener-
getic contribution of the individual groups, a series of
control compounds was synthesized and assayed. The
numbers are simple approximations that are meant to
provide a foundation for future design exercises and not
intended to address the complex energetic nature of the
binding event. The first interaction studied was the carba-
mate-NH via synthesis of 8-amino-2-naphthamidine
(compound 4 Table 2). Compound 4 inhibits urokinase
with a Ki of 0.45 µM (Table 2) showing a tenfold increase
over the naphthamidine parent (approximately 1.5 kcal). A
co-crystal structure of the 8-amino compound, 4 (not
shown, data in Table 1) in complex with urokinase was
shown to reveal a binding orientation nearly identical to
that of the methyl carbamate, where the 8-amino might
donate a long hydrogen bond to Gly216 O
(distance = 3.7 Å). In addition, the potential for an addi-
tional long hydrogen bond to Gly218 O exists (3.4 Å). The
geometry for this hydrogen bond is unfavorable for the
carbamate compounds. In addition to the potential hydro-
gen-bonding interactions, it is possible that van der Waals
packing between the 8-NH and the entrance to S1β might
also contribute binding energy, as proposed for the iodine
of B428. Nevertheless, it is likely that this group is impor-
tant for the binding energetics of the 8-carbamyl com-
pounds and that it could contribute up to approximately
1.5 kcal of binding energy.
If the 8-amino group is responsible for 1.5 kcal of binding
energy, then the remaining 1.5 kcal of binding energy
Research Article  Design of potent urokinase inhibitors Nienaber et al. 557
Table 2
Structure-activity relationship (SAR) for substituted
naphthamidine.
R7* R8* Ki(µM)
†For synthetic reasons, six-membered ring
compounds were initially synthesized in the







































































should arise from the rest of the 8-methyl carbamate.
Comparison of the methyl and benzyl carbamate struc-
tures shows that the carbamate portion of each molecule
makes similar interactions, but that the benzyl methylene
interacts less closely with S1β. The potency difference
between the 8-amino (compound 4) and 8-benzyl-
carbamyl (compound 5) suggests an energetic contribu-
tion by the carbamyl carbonyl. As discussed above, the
carbamyl carbonyl hydrogen bonds with an ordered
solvent and the ester oxygen in close contact with Gly218
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Figure 3
Crystal structures of 8-napthamidines that
access S1β. (a) Stereo depiction of the initial
2Fo–Fc (1σ, purple) and Fo–Fc (2.5σ, green)
maps for the co-crystal structure of
8-benzylcarbamyl-2-napthamidine urokinase at
2.0 Å resolution. Electron density was not
present for the benzyl group but was
continuous for the rest of the inhibitor.
(b) Stereo depiction of the binding of
8-benzylcarbamyl-2-napthamidine to urokinase
showing hydrogen bonds (red dashed lines)
between the carbamate nitrogen and Gly216
as well as the carbamate oxygen and an
ordered solvent molecule at S1β. The Connolly
surface for urokinase is depicted in green.
(c) Stereo diagram depicting the interaction
surface and hydrogen bonding between
8-methylcarbamyl-2-napthamidine (dark blue)
and urokinase (green). Hydrogen bonds are
depicted in red. Atoms are in standard colors.
Cα. The ester oxygen interaction was probed through the
synthesis and testing of 8-methyl urea (compound 8
Table 2) and 8-ethyl amide (compound 7 Table 2) com-
pounds. Each compound showed decreased potency (Ki of
2.1 µM and 2.2 µM, respectively) relative to the methyl
carbamyl compound (compound 6), thus suggesting
subtle interactions at the ester oxygen site. For com-
pounds 7 and 8, modeling predicts that the hydrogen
atoms would interfere with the close packing observed for
the ester oxygen, thereby reducing the inhibitory potency.
A significant portion of the methyl carbamate binding
energy appears to be due to the terminal methyl group, as
estimated by comparing potencies of the 8-benzyl carba-
mate, compound 5, (where the methyl packing interaction
is sterically occluded) and the 8-methyl compound 6. This
energy boost might be estimated assuming that the disor-
dered phenyl group is not negatively effecting the
binding energy of compound 5. The consistent binding of
the naphthamidine scaffold for these analogs allows
assignment of approximate energetic contributions that
provide an experimentally derived map of the binding
sites useful for future drug design cycles.
Redesign of the 8-substituent to change chemical
properties but maintain potency
Breaking down the energetic contributions of the methyl
carbamate and examination of its co-crystal structure pro-
vides a template for the design of other S1β pocket-directed
substituents. These substituents can provide compounds
with improved potency, in vivo properties, and/or selectiv-
ity. The previous analysis demonstrated that the carbamate
nitrogen is important for improved binding and that tradi-
tional medicinal chemistry isosteric substitutes will not
work (urea or ethyl amide). Examination of the carbamate
structure suggests that a six-membered aromatic ring would
fit the carbamate structure and better complement the S1β
site (Figure 4a). This led to the synthesis of a series of 8-N-
linked six-membered ring naphthamidines. Of the rings
tested, an 8-aminopyrimidine compound was the most
potent inhibitor (Ki = 0.03 µM, compound 9 Table 2). In
order to confirm the design concept, a co-crystal structure of
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Figure 4
Structure-based optimization of the 8-position substituent. (a) Design
concept based upon the crystal structure of 8-methylcarbamyl
2-naphthamidine showing the feasibility of incorporating a six-
membered aromatic ring at this site (depicted as orange dashed lines).
The predicted surface interaction (orange for inhibitor and colored by
atom type for the protein) shows a complementary lock-and-key fit
which would be predicted to confer an increase in binding potency.
(b) van der Waals representation of the crystal structure of 8-amino-
pyrimidyl-2-naphthamidine showing binding of the pyrimidyl ring as
predicted by the design concept (shown as dotted surface).
(c) Overlay of the co-crystal structures of the 8-methylcarbamyl
(purple) and 8-amino-pyrimidyl (orange) compounds bound to
urokinase. The ordered solvent molecule is displaced in the 8-amino-
pyrimidyl compound.
8-aminopyrimidyl naphthamidine was completed, and the
structure shows that the pyrimidyl fully occupies S1β
(Figure 4b) and overlays well with the methyl carbamate
structure (Figure 4c). Hence, a second chemically novel
substituent that accesses the S1β pocket and maintains high
binding potency was discovered.
Several six-membered ring analogs (compounds 9–12
Table 2) were prepared to analyze the energetic contribu-
tions of the 8-aminopyridyl compound and to contrast
with the energetic analysis of the 8-methyl carbamate.
The 8-NH is present in both series of inhibitors and
makes nearly identical interactions (Figure 4c) with the
protein. Furthermore, substitution of the 8-NH linker
with an ester (compound 13 Table 2) resulted in a tenfold
loss of potency supporting the energetic mapping of the 
8-NH interactions using compound 4. Because the 8-NH-
pyrimidyl (compound 9) and methyl carbamate com-
pounds (6) bind with similar affinities, the pyrimidyl ring
and methyl carbamate –COOMe are likely to contribute
approximately the same amount of binding energy
(~1.5 kcal) even though their chemical structures are very
different. The structural differences are manifested in the
co-crystal structures where the pyrimidyl group occupies
more of the S1β pocket than the methyl carbamate and dis-
places the ordered solvent molecule that hydrogen bonds
with the carbamate carbonyl. The interaction of the
pyrimidyl group might represent a lock-and-key fit, tradi-
tionally predicted to confer an increase in binding potency
[48]. This is in contrast to the methyl carbamate where
binding energy appears to arise from hydrophobic and
hydrophilic interactions, including the interaction of the
carbamate methyl at the Ser214 dimple that is also dis-
rupted in the pyrimidyl compound. Hence, although the
8-NH interaction of compounds 6 and 9 appears to be
both energetically and structurally similar, the overall
binding interaction for the remainder of the two S1β
groups is different.
Although binding of the pyrimidyl and methyl carbamate
ester groups appears to be driven by different interactions,
they share some common characteristics. One of the
pyrimidyl nitrogens occupies the same site as the carba-
mate ester oxygen and, as observed for the carbamate
series, the addition of a hydrogen atom, such as in com-
pound 11, at this site results in a decrease in binding
energy (compounds 7–8 and 11–12 Table 2). This might
arise because both the 8-phenyl (11, Ki = 1.7 µM) and the
8-pyridyl (12, Ki = 0.17 µM) compounds could place a
hydrogen atom at the carbamate oxygen site. The phenyl
compound is the weakest inhibitor in the six-membered
ring series (naphthamidines 9–12 Table 2), and the pyridyl
is intermediate between the phenyl and pyrimidyl. The
phenyl compound would always place a hydrogen atom at
the carbamate oxygen site, whereas the pyrimidyl would
have an equally probable chance of placing a hydrogen in
the ‘less favorable’ orientation. In addition, it is possible
that a nitrogen would be preferred at both pyrimidyl nitro-
gen sites as the second nitrogen is approximately 3.7 Å
from Gln192 N. At this site a –CH substituent could result
in a steric clash or loss of a favorable long range hydrogen-
bonding interaction. Hence, although the 8-pyrimidyl and
carbamate compounds are chemically different, they
appear to share some common packing interactions at S1β.
Selectivity and the S1β pocket
In the development of a clinical agent, selectivity for the
target protein is important for reducing the potential for
harmful side-effects. This is particularly true for the
trypsin-like family of proteases that have been implicated
in a number of highly regulated processes including blood
coagulation, fibrinolysis and the complement system
[49–51]. To monitor selectivity, inhibition of a series of
closely related trypsin-like proteases was measured in con-
junction with the design process. The naphthamidine lead
compound exhibits specificity over plasmin, tissue plas-
minogen activator and thrombin with limited selectivity
over trypsin and kallikrein (Table 3). Addition of the
8-NH functionality confers an increase in potency for all
proteins tested. Structurally, this is likely to occur because
the 8-NH binding site is highly conserved in all serine
proteases. Building the methyl carbamate into S1β results
in a substantial increase in potency for urokinase, whereas
trypsin (and tissue plasminogen activator) gains less. The
increase of specificity relative to trypsin, however, was a
particular challenge as the naphthamidine parent binds
trypsin and urokinase with nearly equal potencies. The
S1β pocket of bovine trypsin is different from that of uroki-
nase primarily because of an asparagine substitution for
Lys143 [52]; filling this site could result in a change of the
specificity profile. This region is also conserved in human
trypsin [53]. Incorporation of the N-pyrimidyl group,
which occupies S1β more fully, results in a loss of potency
for trypsin while maintaining high potency for urokinase.
Hence, binding at S1β appears to exploit structural differ-
ences between urokinase and trypsin and, thus has
resulted in potent and specific urokinase inhibitors.
Two of the most potent nonpeptidic urokinase inhibitors
reported to date have been discovered using structure-
directed drug design. Naphthamidine served as the start-
ing scaffold and structure-directed optimization began by
accessing a novel binding subpocket, termed S1β, via the 
8-position. The two most potent inhibitors (compounds 6
and 9 Table 2) are chemically diverse but share a common
hydrogen-bonding interaction estimated to contribute
approximately 1.5 kcal of binding energy to each com-
pound. This binding energy was derived from the potency
of the control compound 8-amino naphthamidine (com-
pound 4) and supported by compound 13. The methyl car-
bamyl group further interacts at S1β through other
hydrophilic and hydrophobic interactions. These include
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hydrogen bonding with an ordered solvent molecule and
van der Waals packing of the carbamate ester oxygen and
methyl group. In the pyrimidyl compound, the interaction
at the carbamate ester oxygen-binding site appears to be
preserved, whereas packing of the methyl group is lost.
This loss, however, is accompanied by a gain in van der
Waals interactions between the 6-membered ring and the
S1β pocket. Hence, although compounds 6 and 9 access the
same binding subsite on urokinase, the chemical diversity
of the two substituents gives rise to a variety of binding
interactions that yield nearly identical inhibitory potencies.
In addition, the diversity of these two substituents results
in a filling of S1β by the pyrimidyl group that yields selec-
tivity against other serine proteases including trypsin.
The design strategy applied to urokinase relies on interac-
tions at a previously uncharacterized binding subpocket
adjacent to the primary substrate-binding site. This strat-
egy was necessary because the substrate-binding pockets
typically utilized in structure-directed inhibitor optimiza-
tion towards other serine proteases [33,38] are blocked by
insertion loops in urokinase. Little was known about the
functionality and binding interactions required to confer a
potency increase at S1β, and therefore a strategy of struc-
ture-directed synthesis was adopted to probe the pocket
and begin the drug design process. This led to the discov-
ery of a carbamate series of inhibitors. Further structure-
based drug design yielded the pyrimidyl functionality.
The initial success with urokinase is encouraging because
many important drug targets might lack a large binding
site or multiple anchor sites. Hence, this approach can be
applied to other drug targets for discovery of more potent
and selective inhibitors. 
Structure-based drug design and the synthesis of control
compounds have permitted an initial energetic mapping of
the novel binding subpocket, S1β, in urokinase. This ener-
getic mapping should contribute to future drug design exer-
cises with urokinase as the a priori prediction of binding
affinities can be a very difficult task because of the high
number of variables that must be considered [48]. Although
energetic mapping using X-ray crystal structures and
inhibitory potencies is an approximation, the consistency of
the results presented here suggests a correlation and implies
that the numbers might be applied in future series. This
methodology and knowledge, together with the identifica-
tion of two potent urokinase inhibitors, is being used to
further the development of novel, potent and specific small-
molecule urokinase inhibitors for the treatment of cancer.
Biological implications
Human urokinase (urokinase-type plasminogen activa-
tor, u-PA) has been demonstrated to have a role in the
disease progression of cancer. This protein is composed of
three domains: the catalytic serine protease domain, a
kringle domain and an epidermal growth factor like
domain. The C-terminal serine protease domain is
responsible for activation of the inactive zymogen, plas-
minogen, into the active protease, plasmin. Plasmin, in
turn, is responsible for the degradation of basement mem-
brane and interstitial proteins that facilitates tumor
growth and metastasis. The N-terminal domains serve to
anchor urokinase to the membrane surface through a
specific urokinase receptor (uPAR) but have not been
implicated in the catalytic activity of the enzyme. Hence,
urokinase-mediated cancer progression might be blocked
at two junctions. Firstly, inhibiting the urokinase–uPAR
receptor interaction might indirectly block substrate
cleavage by limiting access to the membrane-bound plas-
minogen. Secondly, urokinase activity might also be
directly blocked through inhibition of the catalytic activity
of the serine protease domain. To effect this second strat-
egy, structure-based drug design has been used to dis-
cover two novel, potent and specific urokinase inhibitors. 
The discovery of novel urokinase inhibitors using struc-
ture-based drug design has been expedited through use of
a new crystal form of human urokinase. This crystal
form arises from a re-engineered urokinase that has been
shown to possess catalytic properties similar to the native
enzyme. The re-engineered protein lacks the N-terminal
domain, yields more efficient crystal packing resulting in
higher resolution structures, and permits formation of
crystalline complexes using the method of compound
soaking. Use of this crystal system has permitted 
structural characterization of a novel binding subsite
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Table 3
Selectivity data for compounds used in this study.
R –H –NH2 –NHCOObenz –NHCOOMe –NHpyr
Human urokinase 5.9 0.45 0.17 0.04 0.03
Human plasminogen 51 6.6 1.7 1.8 3.8
Human t-PA 100 27 41 40 23
Human kallikrein 22 1.9 1.3 1.5 1
Porcine trypsin 7.8 0.2 0.2 0.3 1.6
Human thrombin 85† 5.2 4.3 5.2 3.9
Ki values are given in µM. t-PA, tissue plasminogen activator. *R, substituents are as described in Table 1. †Published value [57].
adjacent to the primary binding pocket and substrate-
binding groove, yielding two new urokinase inhibitors.
These compounds are the most potent urokinase
inhibitors reported to date, and this information is being
used to expedite discovery of an anticancer clinical agent.
Materials and methods
Amidolytic kinetics of urokinase and microurokinase
The effect of synthetic inhibitors on the steady-state amidolytic activity
of urokinase was completed as described [34]. Specifically, synthetic
compounds were tested for inhibitory activity against urokinase
(2–3 nM; S-2444, pyroGlu-Arg-pNA-HCl, 200 µM), human plasma
kallikrein (100 ng ml—1, S-2302, H-D-Pro-Phe-Arg-pNA-2HCl, 330 µM),
human plasmin (18 nM, S-2251, H-D-Val-Leu-Lys-pNA-2HCl, 360 µM),
human α-thrombin (8 nM, S-2302, H-D-Pro-Phe-Arg-pNA-2HCl,
820 µM), human t-PA (1 µg ml–1, S-2288, H-D-Ile-Pro-Arg-pNA-2HCl,
1350 µM) and porcine trypsin (1.25 nM; S-2444, pyroGlu-Arg-pNA-
HCl, 200 µM). Chromogenic substrates were obtained from
DiaPharma Group, Inc. Distributor of Chromogenix. All enzymes were
obtained from commercial sources (kallikrein, t-PA, and trypsin, Sigma;
plasmin, DiaPharma; thrombin, Enzyme Research Laboratories; human
urokinase, Abbokinase, Abbott Laboratories). The assay was performed
in a 96-well polystyrene, flat-bottom plate in a 50 mM Tris/0.15 M NaCl
and 0.5% Pluronic F-68 (Σ P-5556), pH 7.4 (with HCl) buffer. The
compounds were dissolved in dimethylsulfoxide (DMSO), and tested at
0.01–250 µM concentrations in a final reaction volume of 200 µl. The
reactions were initiated by the addition of substrate, and were followed
by the formation of p-nitroanaline at 405 nm at 25°C on a Spectromax
(Molecular Devices) plate reader for 15 min. Ki values were calculated
from the percent inhibition and previously established Km values.
Protein crystallography
Protein was prepared and crystallized as reported previously [34].
Complex structures were obtained by the soaking method using DMSO
as the co-solvent [34] and the solid compound was obtained from the
Abbott chemical repository. Details for the synthesis of these compounds
will be presented elsewhere. Data were collected at 160K as described
[34] and processed using the HKL program suite [54]. Initial electron-
density maps were calculated and complexes refined using the program
package X-PLOR [55]. All electron-density maps were inspected on a
Silicon Graphics INDIGO2 workstation using QUANTA 97, and the ori-
entation of all compounds were clearly visualized in the initial 2Fo–Fc
map. Ordered solvent molecules were identified as positive peaks in the
Fo–Fc map that were 4σ above noise. All data were of high quality to the
highest resolution shell and well refined as summarized in Table 1.
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